EP3512506A4 - Verwendung von pridopidin zur behandlung des rett-syndroms - Google Patents

Verwendung von pridopidin zur behandlung des rett-syndroms Download PDF

Info

Publication number
EP3512506A4
EP3512506A4 EP17851614.2A EP17851614A EP3512506A4 EP 3512506 A4 EP3512506 A4 EP 3512506A4 EP 17851614 A EP17851614 A EP 17851614A EP 3512506 A4 EP3512506 A4 EP 3512506A4
Authority
EP
European Patent Office
Prior art keywords
pridopidine
rett syndrome
treating rett
treating
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17851614.2A
Other languages
English (en)
French (fr)
Other versions
EP3512506A1 (de
EP3512506B1 (de
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Priority to EP22150695.9A priority Critical patent/EP4005570B1/de
Priority to DK22150695.9T priority patent/DK4005570T3/da
Priority to PL17851614T priority patent/PL3512506T3/pl
Publication of EP3512506A1 publication Critical patent/EP3512506A1/de
Publication of EP3512506A4 publication Critical patent/EP3512506A4/de
Application granted granted Critical
Publication of EP3512506B1 publication Critical patent/EP3512506B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
EP17851614.2A 2016-09-16 2017-09-15 Verwendung von pridopidin zur behandlung des rett-syndroms Active EP3512506B1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22150695.9A EP4005570B1 (de) 2016-09-16 2017-09-15 Pridopidin zur verwendung bei der behandlung des rett-syndroms
DK22150695.9T DK4005570T3 (da) 2016-09-16 2017-09-15 Pridopidin til anvendelse behandling af retts syndroe
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22150695.9A Division EP4005570B1 (de) 2016-09-16 2017-09-15 Pridopidin zur verwendung bei der behandlung des rett-syndroms

Publications (3)

Publication Number Publication Date
EP3512506A1 EP3512506A1 (de) 2019-07-24
EP3512506A4 true EP3512506A4 (de) 2020-05-27
EP3512506B1 EP3512506B1 (de) 2022-01-26

Family

ID=61619744

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17851614.2A Active EP3512506B1 (de) 2016-09-16 2017-09-15 Verwendung von pridopidin zur behandlung des rett-syndroms
EP22150695.9A Active EP4005570B1 (de) 2016-09-16 2017-09-15 Pridopidin zur verwendung bei der behandlung des rett-syndroms

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22150695.9A Active EP4005570B1 (de) 2016-09-16 2017-09-15 Pridopidin zur verwendung bei der behandlung des rett-syndroms

Country Status (13)

Country Link
EP (2) EP3512506B1 (de)
JP (1) JP6977029B2 (de)
CN (1) CN109982686A (de)
AU (1) AU2017326013B2 (de)
BR (1) BR112019005040A2 (de)
CA (1) CA3036984C (de)
DK (2) DK3512506T3 (de)
ES (1) ES2909557T3 (de)
HU (1) HUE058314T2 (de)
IL (1) IL265342B2 (de)
MX (1) MX2019003069A (de)
PL (1) PL3512506T3 (de)
WO (1) WO2018053280A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2879631T3 (es) 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046145A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
WO2015112601A1 (en) * 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101319235B1 (ko) 2004-10-13 2013-10-16 아이백스 인터내셔널 게엠베하 4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2013152105A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
ES2879631T3 (es) 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
EP3590512A1 (de) * 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Verwendung von pridopidin zur behandlung von epilepsie
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046145A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
WO2015112601A1 (en) * 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. GEVA ET AL: "Pridopidine Treatment Recovers Gait Abnormalities and Rescues Impaired BDNF Expression in a Rett Syndrome Mouse Model (P3.324)", NEUROLOGY, 9 April 2018 (2018-04-09), pages 1 - 6, XP055687599, Retrieved from the Internet <URL:https://n.neurology.org/content/90/15_Supplement/P3.324> [retrieved on 20200420] *

Also Published As

Publication number Publication date
MX2019003069A (es) 2019-09-02
ES2909557T3 (es) 2022-05-09
CA3036984C (en) 2023-07-18
JP6977029B2 (ja) 2021-12-08
EP4005570A1 (de) 2022-06-01
DK3512506T3 (da) 2022-04-19
EP3512506A1 (de) 2019-07-24
CA3036984A1 (en) 2018-03-22
PL3512506T3 (pl) 2022-05-30
WO2018053280A1 (en) 2018-03-22
EP3512506B1 (de) 2022-01-26
AU2017326013A1 (en) 2019-04-11
CN109982686A (zh) 2019-07-05
BR112019005040A2 (pt) 2019-07-16
EP4005570B1 (de) 2024-05-15
AU2017326013B2 (en) 2020-12-24
JP2019532926A (ja) 2019-11-14
HUE058314T2 (hu) 2022-07-28
IL265342A (en) 2019-05-30
IL265342B2 (en) 2023-06-01
DK4005570T3 (da) 2024-08-19

Similar Documents

Publication Publication Date Title
EP3541932A4 (de) Inhibitoren von crispr-cas9
EP3541396A4 (de) Inhibitoren von cd73-vermittelter immunsuppression
EP3102576B8 (de) Dihydropyrrolopyridininhibitoren von ror-gamma
EP3233846A4 (de) Inhibitoren von bromdomänen
EP3137169A4 (de) Inhibitoren der lysin-spezifischen demethylase-1
EP3189038A4 (de) Inhibitoren von lysinspezifischer demethylase-1
EP3160956A4 (de) Inhibitoren der lysin-spezifischen demethylase-1
EP3125895A4 (de) Substituierte spirocyclische inhibitoren von autotaxin
EP3119401A4 (de) Cenicriviroc zur behandlung von fibrose
EP3191100A4 (de) Cenicriviroc-kombinationstherapie zur behandlung von fibrose
EP3164380A4 (de) Inhibitoren der lysin-spezifischen demethylase-1
EP3373969A4 (de) Glycaninteragierende verbindungen und verfahren zur verwendung
EP3179993A4 (de) Verfahren zur behandlung von depression
EP3512506A4 (de) Verwendung von pridopidin zur behandlung des rett-syndroms
EP3504187A4 (de) Verwendung von pridopidin zur behandlung von funktionalem verfall
EP3134436A4 (de) Behandlung von h-ras-gesteuerten tumoren
EP3164509A4 (de) Inhibitoren der lysin-spezifischen demethylase-1
EP3089964A4 (de) Heteroatomhaltige deoxyuridin-triphosphatase-inhibitoren
EP3137087A4 (de) Östrogenkombination zur behandlung von multipler sklerose
EP3478281A4 (de) Verfahren zur behandlung des prader-willi-syndroms
EP3107902A4 (de) Verbindungen und verfahren zur hemmung von fascin
EP3122349A4 (de) Zusammensetzungen zur behandlung von autodigestion
EP3229813A4 (de) Behandlung von hmgb1-vermittelten entzündungen
EP3384921A4 (de) Neue verwendung von thiopeptin
EP3491129A4 (de) Verfahren zur behandlung von osmidrose

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PRILENIA NEUROTHERAPEUTICS LTD.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602017052889

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0009200000

Ipc: A61K0031451000

A4 Supplementary search report drawn up and despatched

Effective date: 20200430

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20200423BHEP

Ipc: A61K 9/28 20060101ALI20200423BHEP

Ipc: A61K 9/20 20060101ALI20200423BHEP

Ipc: A61K 31/451 20060101AFI20200423BHEP

Ipc: A61P 21/00 20060101ALI20200423BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009961

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210315

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210913

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1464742

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017052889

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220412

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2909557

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220509

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E058314

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220526

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220426

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220526

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017052889

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20220909

Year of fee payment: 6

Ref country code: CZ

Payment date: 20220826

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20220806

Year of fee payment: 6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20221027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220915

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20230627

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230810

Year of fee payment: 7

Ref country code: IE

Payment date: 20230710

Year of fee payment: 7

Ref country code: GB

Payment date: 20230727

Year of fee payment: 7

Ref country code: AT

Payment date: 20230825

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230710

Year of fee payment: 7

Ref country code: PL

Payment date: 20230703

Year of fee payment: 7

Ref country code: FR

Payment date: 20230710

Year of fee payment: 7

Ref country code: DE

Payment date: 20230718

Year of fee payment: 7

Ref country code: BE

Payment date: 20230818

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231004

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20231001

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230915

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230915

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230916

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240705

Year of fee payment: 8